Huang et al. (2022b) combined exosomes with lncRNA by engineering technology, to construct PMs-derived MBNPs (cRGD-Exo-MEG3) modified by c (RGDyK) and loaded with MEG3 for targeted therapy of osteosarcoma. Here, MEG3 is linked to osteosarcoma.